Click here for slides on this topic


SGLT2

Abbreviation for sodium-glucose co-transporter 2.
The following content matched the glossary term: SGLT2

NDEI.org Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results

Top

Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients

NDEI.org Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths

Top

Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial

Top

The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary.

Endocrine Society obesity clinical practice guideline

Top

Summary of guidelines for managing obesity with pharmacologic therapy from the Endocrine Society.

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

Top

Tikkanen I, Narko K, Zeller C, et al; for the EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014;Epub ahead of print. DOI: 10.2337/dc14-1096.

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

Treating the Patient With Type 2 Diabetes and Renal Impairment – References

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Key Take-Home Messages

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Proteinuria

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Follow-Up Pharmacologic Therapy Considerations Metformin

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

1 2 3 Next 

Slide Library Results

Search Results for: SGLT2 Slides Found: 53
CANTATA-D2: Design
CANTATA-D2: Canagliflozin Noninferior to Sitagliptin for A1C Lowering at 52 Weeks
CANTATA-D2: Significantly Greater FPG Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significantly Greater Weight Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significant Reductions in Systolic BP with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-D2: Adverse Events at 52 Weeks
CANTATA-M: Significant A1C Reductions with Canagliflozin Vs Placebo at 26 Weeks
CANTATA-M: Greater Proportion of Subjects Achieved A1C <7.0% with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant FPG Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant Weight Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant Reductions in Systolic BP Seen with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Effect of Canagliflozin Vs Placebo on Lipid Values at 26 Weeks
CANTATA-M: Adverse Events with Canagliflozin Vs Placebo at 26 Weeks
CANTATA-M: Design
Canagliflozin: Renal Considerations
Emplagliflozin SGLT 2 A1C EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Weight Loss EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Insulin EMPA-REG MDI Study | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 EMPA-REG MDI Study | NDEI
SGLT2 Inhibitors Type 2 Diabetes Treatment Slides | NDEI
SGLT Glucose Homeostasis Diabetes Education Slides | NDEI
Reports of Acute Pancreatitis Type 2 Diabetes Drugs | NDEI
SGLT2 Dapagliflozin + Insulin Type 1 Diabetes Treatment Slide | NDEI
Adverse Events Dapagliflozin As Insulin Adjunct in Type 1 Diabetes | NDEI
Dapagliflozin Pharmacokinetics in Type 1 Diabetes SGLT 2 | NDEI
Average Daily Glucose Changes & Insulin Use Dapagliflozin Type 1 Diabetes | NDEI
Dapagliflozin Type 1 Diabetes SGLT2 Data Review | NDEI
EMPA-REG Blood Pressure Lowering With Empagliflozin Type 2 Diabetes Hypertension | NDEI
EMPA-REG Blood Pressure Reductions With Empagliflozin SGLT2 | NDEI PPT
EMPA-REG A1C & Weight Loss Empagliflozin SGLT2 Type 2 Diabetes | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
EMPA-REG BP: A1C, BP, & Weight Reduction With Empagliflozin in Type 2 Diabetes & Hypertension Clinical Significance for HCPs
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
Canagliflozin & Sitagliptin A1C Type 2 Diabetes ENDO2015 PPT | NDEI
Empagliflozin Vs Linagliptin First-Line Type 2 Diabetes Treatment ENDO2015 | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
EMPA-REG OUTCOME Empagliflozin CV Death Reduced Type 2 Diabetes | NDEI
Empagliflozin Reduces Death Type 2 Diabetes EMPA-REG OUTCOME EASD | NDEI
EMPA-REG OUTCOME Empagliflozin Heart Failure Type 2 Diabetes EASD | NDEI
EMPA-REG OUTCOME Empagliflozin A1C High-Risk Type 2 Diabetes | NDEI
Empagliflozin Safety Adverse Events Type 2 Diabetes EMPA-REG OUTCOME | NDEI
EMPA-REG OUTCOME Design Empagliflozin SGLT2 Type 2 Diabetes | NDEI
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
Empagliflozin Reduces Kidney Disease in EMPA-REG OUTCOME CVOT | NDEI
Empagliflozin Renal Outcomes in EMPA-REG OUTCOME CVOT | NDEI
Metabolic Surgery Postoperative Follow-Up for Type 2 Diabetes Guidelines | NDEI